🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection

Found 33 matching trials

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

PHASE2

This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in...

Status

Active Not Recruiting

Location

University of Alabama at Birmingham Cancer Center

Start Date

2020-03-13

Trial ID

NCT04266249

Treatments Being Tested

Docetaxel Lumpectomy Mastectomy Nab-paclitaxel Paclitaxel Pertuzumab Radiation Therapy Trastuzumab Trastuzumab Emtansine

Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer

PHASE3

This is a multicenter, open label, non-inferiority, randomized controlled c...

Status

Recruiting

Location

Sunyat-sen Memorial Hospital

Start Date

2021-12-20

Trial ID

NCT05159193

Treatments Being Tested

pegylated liposomal doxorubicin (PLD)cyclophosphamide (C)trastuzumab (H)pertuzumab (P)docetaxel (T)docetaxel (T)carboplatin (Cb)trastuzumab (H)pertuzumab (P)

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

PHASE2

Doctors leading this study would like to learn about providing cancer treat...

Status

Recruiting

Location

Lagos State University Teaching Hospital

Start Date

2025-03-18

Trial ID

NCT06348134

Treatments Being Tested

Trastuzumab emtansine Pertuzumab Injection Docetaxel Tamoxifen Letrozole Goserelin

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.

PHASE3

This is a randomized, double-blind, multicenter trial，parallel control desi...

Status

Completed

Location

Fudan University Cancer Hospital

Start Date

2020-11-23

Trial ID

NCT04629846

Treatments Being Tested

Trastuzumab QL1209 Pertuzumab Docetaxel surgery

A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer

PHASE3

To evaluate the efficacy and safety of SHR-A1811 with or without pertuzumab...

Status

Active Not Recruiting

Location

The First Affiliated Hospital of Nanjing Medical University

Start Date

2023-10-16

Trial ID

NCT06057610

Treatments Being Tested

SHR-A1811 Injection SHR-A1811 Injection ； Pertuzumab Injection Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection

A Study for the Neoadjuvant Treatment of Breast Cancer

PHASE4

Due to the unique advantages of albumin-bound paclitaxel, several studies i...

Status

Recruiting

Location

2nd Affiliated Hospital, School of Medicine, Zhejiang University

Start Date

2022-07-10

Trial ID

NCT05420454

Treatments Being Tested

Docetaxel Carboplatin Trastuzumab Pertuzumab Nab paclitaxel Epirubicin Cyclophosphamide Docetaxel Epirubicin Cyclophosphamide Nab paclitaxel

Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging

PHASE2

This study evaluates HER2-PET/CT-guided dynamic optimization of neoadjuvant...

Status

Not Yet Recruiting

Location

Multiple Locations

Start Date

2026-05-01

Trial ID

NCT07527806

Treatments Being Tested

Trastuzumab (Herceptin)Pertuzumab Combination product: Trastuzumab + Pertuzumab Docetaxel or Nab-paclitaxel carboplatin CDK4/6 inhibitor Aromatase Inhibitor (AI)ADC

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

PHASE3

This Phase III, randomized, two-arm, open-label, multicenter study will eva...

Status

Active Not Recruiting

Location

Arizona Clinical Research Center, Inc

Start Date

2022-07-18

Trial ID

NCT05296798

Treatments Being Tested

Phesgo Giredestrant Docetaxel Paclitaxel LHRH Agonist Optional Endocrine Therapy of Investigator's Choice

A Study for the Adjuvant Treatment of Breast Cancer

PHASE4

Studies on postoperative adjuvant albumin paclitaxel in domestic breast can...

Status

Recruiting

Location

2nd Affiliated Hospital, School of Medicine, Zhejiang University

Start Date

2022-07-10

Trial ID

NCT05420467

Treatments Being Tested

Docetaxel Carboplatin Trastuzumab Pertuzumab Nab paclitaxel Epirubicin Cyclophosphamide Docetaxel Epirubicin Cyclophosphamide Nab paclitaxel Cyclophosphamide

A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer

PHASE2

The study is being conducted to evaluate the clinical efficacy of HLX87 in ...

Status

Not Yet Recruiting

Location

Multiple Locations

Start Date

2026-01-27

Trial ID

NCT07294534

Treatments Being Tested

HLX87+HX22 HLX87 + Pertuzumab TCbHP

Previous Next